Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.66 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9982587 | 0.86 | HSD11B1 (0.63) | HSD11B1HSD11B2HDAC4HDAC1 | |
| SCHEMBL8510078 | 0.86 | HSD11B1 (0.69) | HSD11B1HSD11B2ADRA1AHDAC1 | |
| SCHEMBL8512119 | 0.86 | HSD11B1 (0.69) | HSD11B1HSD11B2ADRA1AHDAC1 | |
| SCHEMBL9982523 | 0.86 | HSD11B1 (0.77) | HSD11B1HSD11B2HDAC4 | |
| SCHEMBL3667504 | 0.83 | HSD11B1 (0.86) | HSD11B1HSD11B2 | |
| SCHEMBL8511579 | 0.82 | HSD11B1 (0.72) | HSD11B1HSD11B2ADRA1AHDAC1 | |
| SCHEMBL8508946 | 0.81 | HSD11B1 (0.61) | HSD11B1HSD11B2HDAC4HDAC1 | |
| SCHEMBL9982162 | 0.80 | HSD11B1 (0.65) | HSD11B1HSD11B2HDAC1 | |
| SCHEMBL3663888 | 0.79 | HSD11B1 (1.00) | HSD11B1HSD11B2ACVR1 | |
| SCHEMBL9982521 | 0.78 | HSD11B1 (0.63) | HSD11B1HSD11B2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459549-B1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-19 | — | — | EP | claimed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | claimed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | claimed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OXGR1 | HSD11B1 1963/4885HSD11B2 1686/4885IDH1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.